Gilead Sciences, Inc. (NASDAQ:GILD)
CAPS Rating:
A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
The World's Greatest Investing Community
A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
I noticed Gilead Sciences in my best 25 large cap pe/roe screen. This screen has outperformed the market by about 15% per year during the last 9 years. Gilead is swimming in cash and boasts a 5 yr average historical roe of 49%. The company is swimming in cash. Sales growth has been spectacular for the last five years and the company even managed significant growth in 2009. Despite all of these positives, Gilead is selling for low multiples compared to its history. Current p/bv is 7.35, 5 yr average p/bv is 11. Current p/sales is 6.46, 5yr average is 10.5. P/E based on 2010 estimated earnings is 15. The five year average p/e is 24. The timing seems right. Gilead can be viewed as a tech stock and tech stocks usually outperform in December. Stockscouter 9, Caps 5.
How were you able to calculate the 15% outperformance over the last 9 years? Does CAPS have a function that allows you to 'back-test' your portfolio? Thanks for this post - I agree with the GILD call.
I subscribe to a Zacks service called Research Wizard. This service allows me to backtest stock screens to December 15, 1999. I do not think that CAPS offers a backtesting function.